JACC in a Flash | RALES, EMPHASIS-HF; 6MWT Identifies ATTR-CA in High-Risk Patients; More

Featured topics and Editors' Picks from all of ACC's JACC Journals.

The results from several of the hottest trials presented at ESC Heart Failure 2024 and EuroPCR 2024 were simultaneously published in JACC Journals in May. Check out some of the highlights below and click here for access to a complete list of simultaneous publications from these and other recent scientific meetings.

Journal of the American College of Cardiology
Does MRA Reduce Risk in Patients With HF and Acute CKD?

Mineralocorticoid receptor antagonists (MRAs) reduce the risk of cardiovascular death or heart failure (HF) hospitalization in patients with both HF with reduced ejection fraction (HFrEF) and a decreased glomerular filtration rate (eGFR) <30 ml/min/1.73 m2, according to an analysis of patient data from the RALES and EMPHASIS-HF trials, presented at ESC Heart Failure 2024.

Journal of the American College of Cardiology
Semaglutide Reduces NT-proBNP in HFpEF Patients

The GLP1RA semaglutide reduces N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with obesity-related heart failure with preserved ejection fraction (HFpEF), and it may hold greater benefits for patients who start treatment with a higher baseline NT-proBNP, according to a prespecified secondary analysis of pooled data from two double-blind trials, STEP-HFpEF and STEP-HFpEF DM, presented at ESC Heart Failure 2024.

Journal of the American College of Cardiology
Prognostic Role For 6MWT in Patients With ATTR-CA?

The six-minute walk test (6MWT) is a reliable and accurate prognosticator of outcomes in patients with transthyretin cardiac amyloidosis (ATTR-CA), according to a retrospective analysis by Adam Ioannou, MBBS, BSc, et al., presented at ESC Heart Failure 2024.

Journal of the American College of Cardiology
MRR Independent Predictor of All-Cause Mortality, HF Hospitalization in STEMI Patients

Microvascular resistance reserve (MRR) measured directly after primary PCI was an independent predictor of all-cause mortality or hospitalization for heart failure (HF) in patients with a STEMI over long-term follow-up, according to the results of a pooled analysis presented during EuroPCR 2024.

Journal of the American College of Cardiology
ORBITA-STAR: Similarity Score of Induced Angina Symptoms Predicts Post PCI Improvement

The closer the similarity between patient-reported and medically induced angina symptoms, the more likely these symptoms will be improved following PCI, according to ORBITA-STAR, an n-of-1 placebo-controlled study presented at EuroPCR 2024.

Journal of the American College of Cardiology
MRR as a Predictor of MACCE in STEMI Patients?

Microvascular resistance reserve (MRR), as a measure of coronary microvascular dysfunction (CMD), can be a strong predictor of major adverse cardiovascular and cerebrovascular events (MACCE) at 12 months in patients with STEMI, according to a study by Tsung-Ying Tsai, MD, Patrick W. Serruys, MD, PhD, FACC, et al., presented at EuroPCR 2024 and simultaneously published in JACC: Cardiovascular Interventions.

Clinical Topics: Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Stable Ischemic Heart Disease, Vascular Medicine, Acute Heart Failure, Interventions and Vascular Medicine, Chronic Angina

Keywords: Cardiology Magazine, ACC Publications, Heart Failure, Percutaneous Coronary Intervention, Hyperkalemia, Angina Pectoris, ST Elevation Myocardial Infarction

< Back to Listings